Antibiotics Improve the Treatment Efficacy of Oxaliplatin-Based but Not Irinotecan-Based Therapy in Advanced Colorectal Cancer Patients
Table 4
Univariate and multivariate analyses of the relationship between the response to oxaliplatin- or irinotecan-based therapy and the patients’ background and severe neutropenia.
n (%)
Oxaliplatin-based therapy
Irinotecan-based therapy
Univariate analysis
Multivariate analysis
Univariate analysis
Multivariate analysis
OR (95% CI)
OR (95% CI)
Sex
Male
67 (55.8)
0.611
1.81 (0.722–3.1222)
0.5896
0.8222
1.352 (0.745–3.089)
0.7856
Female
53 (44.2)
Age
≧65
68 (56.7)
0.249
1.861 (0.822–2.156)
0.3902
0.3389
1.698 (0.722–1.899)
0.4256
<65
52 (43.3)
Antibiotics
Untreated
53 (44.2)
0.0159
2.815 (1.656–7.228)
0.0155
0.5439
1.7989 (0.754–2.156)
0.6001
Treated
67 (55.8)
Line of chemotherapy
First line
81 (67.5)
0.4489
1.525 (0.758–2.115)
0.4998
0.5668
1.554 (0.564–2.225)
0.7054
Second-line
39 (32.5)
Severe (grade 3 or 4) neutropenia
Negative
93 (77.5)
0.5564
0.789 (0.252–2.355)
0.4655
0.6612
1.882 (0.711–2.225)
0.5154
Positive
27 (22.5)
Operation history
Negative
34 (28.3)
0.191
0.289 (0.896–6.283)
0.174
0.311
0.7988 (0.315–8.256)
0.3598
Positive
86 (71.7)
Ras status
Wild type
63 (52.5)
0.8406
1.458 (0.787–1.552)
0.7154
0.7723
1.615 (0.498–2.125)
0.782
Mutant type
57 (47.5)
Cancer primary site
Right side colon
42 (35.0)
0.721
0.778 (0.324–2.336)
0.747
0.6129
0.756 (0.225–3.089)
0.7255
Left side colon
78 (65.0)
OR: odds ratio; CI: confidence interval. was calculated using Pearson’s chi-square test.
